Combining vaccines targeting HER2-related antigens with oncolytic herpes virus therapy can leverage the high immunogenicity of HSV vectors to facilitate strong tumor-localized inflammation and induce an in situ cancer vaccination effect [18,19,20]. The gene discussed is ERBB2; the disease is cancer.